What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?

What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?

Bibliographic Details
Main Authors:	Malki, Manar, Mangera, Altaf, Reid, Sheilagh, Inman, Richard, Chapple, Christopher
Format:	Online
Language:	English
Published:	Polish Urological Association 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074718/

Similar Items

300 IU vs. 200 IU of OnabotulinumtoxinA for detrusor overactivity
by: Persu, Cristian
Published: (2014)

OnabotulinumtoxinA in the treatment of neurogenic bladder
by: Gulamhusein, Aziz, et al.
Published: (2012)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
by: Zhang, Rui, et al.
Published: (2015)

OnabotulinumtoxinA for the treatment of overactive bladder
by: Cox, Lindsey, et al.
Published: (2014)

Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity
by: Leitner, Lorenz, et al.
Published: (2016)

Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX®) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective
by: Hamid, Rizwan, et al.
Published: (2014)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
by: Zhou, Xin, et al.
Published: (2015)

Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Cheng, Tao, et al.
Published: (2016)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
by: Andersson, Karl-Erik
Published: (2013)

Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
by: Hoag, Nathan, et al.
Published: (2016)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
by: Freemantle, Nick, et al.
Published: (2016)

The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty
by: El-Azab, Ahmed S., et al.
Published: (2013)

CLCR optimal input design for IS and IU plants
by: Cs., Bányász, et al.
Published: (2002)

Erratum to: OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
by: Ginsberg, David, et al.
Published: (2014)

Anti-Xa activities following 5,000 IU and 7,500 IU of s.c. dalteparin in critically ill patients and 5,000 IU in medical patients: a prospective randomized study
by: Heinz, GH, et al.
Published: (2013)

Vitamin D supplementation in older people (VDOP): Study protocol for a randomised controlled intervention trial with monthly oral dosing with 12,000 IU, 24,000 IU or 48,000 IU of vitamin D3
by: Schoenmakers, Inez, et al.
Published: (2013)

OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
by: Ginsberg, David, et al.
Published: (2013)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility
by: Wang, Chung-Cheng, et al.
Published: (2016)

Changes in Dickkopf-1 (DKK1) and Sclerostin following a Loading Dose of Vitamin D2 (300,000 IU)
by: Sankaralingam, A., et al.
Published: (2014)

IU.R Residential Urban Interfaces. Strategies and tools for a renewal project
by: Sabrina Borgianni
Published: (2012-10-01)

The highest (3600 IU) reported overdose of insulin glargine ever and management
by: Karatas, Fatih, et al.
Published: (2015)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
by: Russell, Michael Bjørn
Published: (2011)

OnabotulinumtoxinA in the treatment of refractory chronic cluster headache
by: Christian Lampl, et al.
Published: (2018-06-01)

Pregnancy outcomes following exposure to onabotulinumtoxinA†
by: Brin, Mitchell F., et al.
Published: (2015)

The Role of OnabotulinumtoxinA in Urology: What Is the Next Step?
by: Moon, Hong Sang
Published: (2015)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
by: Gooriah, Rubesh, et al.
Published: (2015)

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
by: Hsiao, Sheng-Mou, et al.
Published: (2016)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder
by: Jiang, Yuan-Hong, et al.
Published: (2014)

Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery
by: Liao, Chun-Hou, et al.
Published: (2016)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Al-Ghazo, Mohammed A., et al.
Published: (2011)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
by: Sievert, K-D, et al.
Published: (2014)

Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity
by: Leitner, Lorenz, et al.
Published: (2014)

Botulinum Toxin in Neurogenic Detrusor Overactivity
by: D'Ancona, Carlos Arturo Levi, et al.
Published: (2012)

Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
by: Robertson, Carrie E, et al.
Published: (2012)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
by: Aurora, Sheena, et al.
Published: (2011)

Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks
by: Oterino, A., et al.
Published: (2011)

Multichannel Electromyographic Mapping to Optimize OnabotulinumtoxinA Efficacy in Cervical Dystonia
by: Kilbane, Camilla, et al.
Published: (2012)

OnabotulinumtoxinA injections for atypical odontalgia: an open-label study on nine patients
by: García-Sáez R, et al.
Published: (2018-08-01)

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety
by: Szok, Délia, et al.
Published: (2015)

OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review
by: Dashtipour, Khashayar, et al.
Published: (2015)